Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 13 studies | 21% ± 6% | |
macrophage | 12 studies | 23% ± 7% | |
endothelial cell | 12 studies | 23% ± 7% | |
classical monocyte | 11 studies | 25% ± 10% | |
oligodendrocyte | 11 studies | 26% ± 11% | |
non-classical monocyte | 10 studies | 25% ± 11% | |
monocyte | 9 studies | 24% ± 4% | |
plasmacytoid dendritic cell | 8 studies | 21% ± 6% | |
ciliated cell | 6 studies | 21% ± 3% | |
adipocyte | 6 studies | 22% ± 7% | |
myeloid cell | 5 studies | 23% ± 7% | |
basal cell | 5 studies | 24% ± 6% | |
astrocyte | 5 studies | 28% ± 8% | |
epithelial cell | 4 studies | 36% ± 6% | |
hepatocyte | 4 studies | 36% ± 13% | |
glutamatergic neuron | 4 studies | 42% ± 11% | |
oligodendrocyte precursor cell | 4 studies | 20% ± 3% | |
dendritic cell | 4 studies | 26% ± 13% | |
plasma cell | 3 studies | 27% ± 8% | |
lymphocyte | 3 studies | 16% ± 0% | |
abnormal cell | 3 studies | 24% ± 3% | |
GABAergic neuron | 3 studies | 36% ± 4% | |
pericyte | 3 studies | 19% ± 1% | |
alveolar macrophage | 3 studies | 28% ± 10% | |
goblet cell | 3 studies | 22% ± 9% | |
interneuron | 3 studies | 36% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6994.68 | 1445 / 1445 | 100% | 64.10 | 183 / 183 |
lung | 100% | 12658.22 | 578 / 578 | 100% | 76.39 | 1155 / 1155 |
skin | 100% | 9912.00 | 1809 / 1809 | 100% | 115.59 | 472 / 472 |
breast | 100% | 11124.04 | 459 / 459 | 100% | 72.37 | 1117 / 1118 |
prostate | 100% | 10121.31 | 245 / 245 | 100% | 47.79 | 501 / 502 |
uterus | 100% | 10862.16 | 170 / 170 | 100% | 73.64 | 458 / 459 |
ovary | 100% | 11799.41 | 180 / 180 | 100% | 61.87 | 429 / 430 |
thymus | 100% | 9657.30 | 653 / 653 | 99% | 55.66 | 601 / 605 |
liver | 100% | 11185.47 | 226 / 226 | 99% | 43.87 | 403 / 406 |
bladder | 100% | 8931.14 | 21 / 21 | 99% | 64.17 | 500 / 504 |
stomach | 100% | 6030.03 | 359 / 359 | 99% | 40.38 | 283 / 286 |
intestine | 100% | 8685.38 | 966 / 966 | 98% | 38.67 | 519 / 527 |
pancreas | 99% | 4375.75 | 326 / 328 | 99% | 62.59 | 176 / 178 |
kidney | 100% | 6818.64 | 89 / 89 | 98% | 51.87 | 884 / 901 |
brain | 96% | 5781.29 | 2530 / 2642 | 100% | 54.60 | 705 / 705 |
adrenal gland | 100% | 7747.03 | 258 / 258 | 96% | 31.76 | 220 / 230 |
adipose | 100% | 11380.75 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 82.33 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 79.25 | 29 / 29 |
spleen | 100% | 18419.58 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 78.80 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 22.98 | 1 / 1 |
blood vessel | 100% | 8102.92 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 4091.34 | 839 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 6510.90 | 871 / 929 | 0% | 0 | 0 / 0 |
muscle | 89% | 2574.80 | 716 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043434 | Biological process | response to peptide hormone |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0051607 | Biological process | defense response to virus |
GO_0001932 | Biological process | regulation of protein phosphorylation |
GO_0060337 | Biological process | type I interferon-mediated signaling pathway |
GO_0090140 | Biological process | regulation of mitochondrial fission |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006952 | Biological process | defense response |
GO_0070721 | Cellular component | ISGF3 complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0042802 | Molecular function | identical protein binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0044389 | Molecular function | ubiquitin-like protein ligase binding |
GO_0005515 | Molecular function | protein binding |
Gene name | STAT2 |
Protein name | STAT2 protein Signal transducer and activator of transcription 2 (p113) Signal transducer and activator of transcription Signal transducer and activator of transcription 2 Signal transducer and activator of transcription 2 (cDNA, FLJ79415, highly similar to Signal transducer and activator of transcription 2) |
Synonyms | hCG_24995 |
Description | FUNCTION: Signal transducer and activator of transcription that mediates signaling by type I interferons (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with IRF9/ISGF3G to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state . In addition, has also a negative feedback regulatory role in the type I interferon signaling by recruiting USP18 to the type I IFN receptor subunit IFNAR2 thereby mitigating the response to type I IFNs . Acts as a regulator of mitochondrial fission by modulating the phosphorylation of DNM1L at 'Ser-616' and 'Ser-637' which activate and inactivate the GTPase activity of DNM1L respectively . . |
Accessions | R9QE71 R9QE65 R9QDZ0 B4DHE0 R9QG81 ENST00000418572.7 R9QE63 R9QG91 A0A494C164 R9QG88 ENST00000314128.9 [P52630-3] A0A494C1L3 ENST00000698186.1 R9QF97 G3V319 R9QDY3 R9QDW5 R9QE53 R9QDY7 ENST00000651301.1 ENST00000652398.1 R9QF99 ENST00000557235.5 [P52630-4] R9QDW3 R9QE44 A0A8V8TLG8 R9QF58 R9QGC0 ENST00000652741.1 ENST00000698180.1 R9QFA6 ENST00000651915.1 A0A8V8TLJ4 ENST00000652624.1 R9QFC5 B4DLC8 ENST00000650805.1 ENST00000698193.1 R9QFA2 ENST00000698192.1 [P52630-3] ENST00000555646.1 A0A494C0B5 A0JLQ9 R9QG79 P52630 |